*The search scope is limited to the products and news section of this site
*The search scope is limited to the products and news section of this site
On Jan. 9, 2023, Genuine Biotech, together with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as "Fosun Pharma"), donated 100 million yuan's worth of oral drug for COVID-19, Azvudine, to rural areas in China through the Shanghai Fosun Foundation (hereinafter referred to as "Fosun Foundation"). The medicines will be donated in several phases to rural areas in Midwestern China, covering 180 counties.
On Jan. 6, 2023, the General Office of the National Health Commission and the General Department of the National Administration of Traditional Chinese Medicine released the Diagnosis and Treatment Guideline for COVID-19 (Tentative 10th Edition), and Azvudine Tablets is the only Chinese oral small-molecule drug for the treatment of COVID-19 recommended.
Ten years of perseverance with uncompromising dedication.No effort will go in vain, and success only comes through hard work!The year of 2022 marks a significant milestone in the development of Genuine Biotech.
The celebratory year of 2022 has come and gone. In 2023, Genuine Biotech will continue to focus on R&D as the driving force, further improve its R&D team, recruit international talents, enhance the R&D platforms, and expand product pipelines to address unmet clinical needs with newer and better treatment options, so as to improve human health through genuine pharmaceutical innovation.
Recently, a clinical trial for the oral small-molecule antiviral drug Azvudine tablets for post-exposure prophylaxis of COVID-19 infection was approved in the Philippines under a strategic collaboration between Genuine Biotech and Fosun Pharma.
Azvudine tablets is the first oral small-molecule antiviral drug for the treatment of COVID-19 developed in China with fully independent intellectual property. On Jul. 25, 2022, it was approved by NMPA for the treatment of common COVID-19 in adults. On Aug. 9, 2022, the General Office of the Nationa...
On Dec. 7, 2022, Guangdong Pharmaceutical Association published the Clinical Pharmacy Guideline for Antiviral Treatment of COVID-19 (Updated Version), which aims to provide detailed guidance for rational and safe clinical use of drugs. Azvudine, the new oral antiviral COVID-19 treatment developed in...
In the evening of Nov. 18, 2022, Henan Genuine Biotech Co., Ltd. (hereinafter referred to as "our company" or "Genuine Biotech") found that Shenzhen Nepstar Pharmacy retailed our drug Azvudine tablets online. Our company paid great attention to this unexpected situation and immediately arranged spec...
On Nov. 11, the Comprehensive Team for Joint Prevention and Control Mechanism of the State Council issued the "Notice on Further Optimizing the Prevention and Control Measures of COVID-19 in A Scientific and Precise Manner". "Measure 13" of the Notice clearly states to "Accelerate the stockpiling of...
Henan Genuine Biotech Co., Ltd. (hereinafter referred to as "Genuine Biotech") announced that the IND clinical trial application for CL-197, a next-generation oral long-acting HIV drug candidate developed by Genuine Biotech, was formally approved by the Center for Drug Evaluation (CDE) of the Nation...
Copyright © 2022 河南真实生物科技有限公司 All Rights Reserved 京ICP备2021026784号-1
